Third, in a post-hoc exploratory analysis, the investigators evaluated expression of PD-L1 in available pretreatment tumor specimens; 160 (72 %) patients were assessable for tumor cell PD-L1 expression, and 137 (62 %) patients were assessable for PD-L1 expression in infiltrating immune cells. The gene discussed is CD274; the disease is neoplasm.